Richter files FYLREVY application and Richter Gedeon stock trades at EUR 34.66

Published on 10/21/2026 at 11:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 14, Richter said FYLREVY could be the first US E4 menopause therapy if approved. Richter Gedeon stock has 7 analyst views listed.

Development pipeline meets calendar

FYLREVY could become the first US E4 menopause therapy if approved, following the October 14, 2026 filing acceptance.
The phase 3 program enrolled 2,576 postmenopausal women across five countries.
Richter Gedeon stock trades at EUR 34.66 at 11:21 a.m. CEST at Lang & Schwarz on October 21, 2026.
Richter Gedeon is scheduled to release third-quarter 2026 results on November 9, 2026.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Richter Gedeon (HU0000123096) stock was trading at EUR 34.66 at Lang & Schwarz on October 21, 2026 at 11:21 a.m. CEST. In its October 14 announcement, Gedeon Richter said the U.S. Food and Drug Administration had accepted its new drug application for FYLREVY.

FYLREVY opens a US pathway

The filing concerns an orally administered estetrol-based estrogen therapy for menopause symptoms. If approved, FYLREVY would be the first menopausal hormone therapy containing E4 on the U.S. market, according to MarketScreener in its October 14, 2026 report.

The clinical base is substantial. The two confirmatory phase 3 studies enrolled 2,576 postmenopausal women across Europe, Russia, the United States, Canada and Latin America. Richter already commercializes FYLREVY in Hungary, the Czech Republic, Slovakia, Finland and Sweden, giving the U.S. filing a commercial track record.

What comes next for Richter?

The next scheduled company date is the third-quarter 2026 earnings release on November 9, 2026, according to the calendar shown by MarketScreener. That report will give investors a nearer-term test of operating performance while the FDA process develops.

MarketScreener lists seven analyst opinions and an average target of HUF 13,214.57 against a last close of HUF 12,640.00. The figures are a consensus reference, not a forecast from Richter, and they sit alongside the separate U.S. regulatory catalyst.

Stock price and reporting date

The company is listed on the Budapest Stock Exchange and operates in pharmaceuticals. Its investor page lists the first-half 2026 earnings presentation dated August 7, 2026, while the next reporting date is November 9, 2026.

Richter Gedeon stock was trading at EUR 34.66 at Lang & Schwarz on October 21, 2026 at 11:21 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.